PC-PLC is involved in osteoclastogenesis induced by TNF-α through upregulating IP3R1 expression

FEBS Lett. 2012 Sep 21;586(19):3341-8. doi: 10.1016/j.febslet.2012.07.015. Epub 2012 Jul 20.

Abstract

The precise mechanism of how TNF-α promotes osteoclast formation is not clear. Previous reports show TNF-α targets molecules that regulate calcium signaling. Inositol-1,4,5-trisphosphate receptors (IP3Rs) are important calcium channel responsible for evoking intracellular calcium oscillation. We found that TNF-α increased the expression of IP3R1 and promoted osteoclastogenesis in RANKL-induced mouse BMMs. Phosphatidylcholine-specific phospholipase C (PC-PLC) specific inhibitor D609 eliminated the upregulation of IP3R1 by TNF-α, and decreased the autoamplification of nuclear factor of activated T-cells 1 (NFATc1), thus resulted in less osteoclasts formation. However, D609 did not inhibit RANKL-induced osteoclastogenesis. Our data suggest TNF-α promotes RANKL-induced osteoclastogenesis, at least partially, through PC-PLC/IP3R1/NFATc1 pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Base Sequence
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / metabolism
  • Bone Resorption / etiology
  • Bone Resorption / metabolism
  • Bone Resorption / pathology
  • Bridged-Ring Compounds / pharmacology
  • Calcium Signaling / drug effects
  • Cell Differentiation / drug effects
  • Cell Differentiation / physiology
  • DNA Primers / genetics
  • Inositol 1,4,5-Trisphosphate Receptors / genetics
  • Inositol 1,4,5-Trisphosphate Receptors / metabolism*
  • Mice
  • NFATC Transcription Factors / metabolism
  • Norbornanes
  • Osteoclasts / cytology
  • Osteoclasts / drug effects
  • Osteoclasts / metabolism*
  • Phosphodiesterase Inhibitors / pharmacology
  • RANK Ligand / metabolism
  • Reactive Oxygen Species / metabolism
  • Thiocarbamates
  • Thiones / pharmacology
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / metabolism*
  • Up-Regulation / drug effects

Substances

  • Bridged-Ring Compounds
  • DNA Primers
  • Inositol 1,4,5-Trisphosphate Receptors
  • NFATC Transcription Factors
  • Nfatc1 protein, mouse
  • Norbornanes
  • Phosphodiesterase Inhibitors
  • RANK Ligand
  • Reactive Oxygen Species
  • Thiocarbamates
  • Thiones
  • Tnfsf11 protein, mouse
  • Tumor Necrosis Factor-alpha
  • tricyclodecane-9-yl-xanthogenate
  • Type C Phospholipases
  • phosphatidylcholine-specific phospholipase C